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Abstract
Purpose In lung cancer, the preservation of well-being is warranted given the limited prognosis. Chemotherapy may negatively
influence health-related quality of life (HRQoL) due to adverse events. However, patients’ judgement about this negative impact
is not well understood. We examined the relationship between expectations, feelings about side effects, and satisfaction with
therapy and (HR)QoL in advanced-stage thoracic cancer and investigated which of these factors has the highest impact on
(HR)QoL.
Methods Sixty-nine patients completed the Cancer Therapy Satisfaction Questionnaire (CTSQ), the World Health Organization
Quality of Life-BREF (WHOQOL-BREF), and the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC QLQ-C30). Multiple regression analyses were performed to investigate the relation of the
CTSQ domains (i.e., expectations of therapy, feelings about side effects, satisfaction with therapy) with (HR)QoL and simple
regression analyses to identify the factors of the CTSQ domain that was most often associated with (HR)QoL.
Results Feelings about side effects were associated with the (HR)QoL domain/scale scores (i.e., WHOQOL-BREF domains: β =
0.36 to 0.58; EORTCQLQ-C30 scales: β = 0.33 to 0.61) except social relationships of theWHOQOL-BREF. Low-grade adverse
events were related to feelings about side effects (β = − 0.326; P = 0.007).
Conclusions Patients experiencing negative feelings about side effects have worse (HR)QoL. Additional care should be provided
to prevent low-grade adverse events.
Keywords Cancer Therapy SatisfactionQuestionnaire . Psycho-oncology . Adverse events . Anti-neoplastic therapy . Non-small
cell lung cancer
Introduction
In patients with advanced-stage lung cancer, the preservation
of their well-being is warranted given their, in general, limited
prognosis [1, 2]. Chemotherapy may have negative impact on
patients’ health-related quality of life (HRQoL) due to side
effects [3]. However, it is not well understood what aspect of
chemotherapy causes this potential negative effect on QoL.
The Cancer Therapy Satisfaction Questionnaire (CTSQ) is
an instrument that assesses patients’ expectations, their feel-
ings about side effects, and their satisfaction with therapy.
Application of this questionnaire gives more insight in pa-
tients’ view on treatment.
Although several publications reported about patients’ sat-
isfaction with care [4–6], patients’ opinions related to side
effects were not evaluated in these studies. Moreover, in a
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study by Rha et al., it was observed that clinicians
underestimated the impact of side effects compared to pa-
tients. In addition, physicians rated different symptoms (i.e.,
nausea and vomiting) as most problematic than patients (i.e.,
fatigue and anorexia) did [7]. The CTSQ assesses the feelings
patients have about treatment [8]. As such, the CTSQ could
inform physicians about patients’ treatment-related opinions,
which may facilitate the management of (HR)QoL. For in-
stance, if a patient scores low on the feelings about side effects
domain of the CTSQ, this is a clear indicator that they are
bothered by side effects. Subsequent identification and ade-
quate management of the experienced side effects may offer
opportunities to maintain (HR)QoL at an acceptable level.
However, the CTSQ may also be useful in the process of
clinical decision making. In many patients with advanced can-
cer, a physician’s decision to start with treatment is related to a
patient’s functional status, comorbidity, and potential toxicity
[9, 10], whilst patients often focus on survival benefits [10, 11]
and may accept a decrease in QoL [12]. Moreover, patients
with cancer would like to be involved in treatment decisions
[13]. A considerable proportion (38.3%; n = 49) of patients
with lung cancer preferred to have some input in treatment
decision making or would like shared treatment decisions.
However, this was achieved in only 46.9% (n = 23) of the 49
cases [14]. Therefore, exploring a patient’s treatment-related
opinion is important as they could have a different understand-
ing of survival rates and the impact of side effects on
(HR)QoL than their physicians.
In previous studies, we and others have shown that the
domains of the CTSQ (i.e., expectations of therapy, feelings
about side effects, satisfaction with therapy) are related to
(HR)QoL [15, 16]. In this study, we investigate which of the
CTSQ domains are associated with (HR)QoL at the end of
treatment in patients with advanced-stage lung cancer and me-
sothelioma. In addition, we assess which underlying factors
(i.e., sociodemographic and clinical variables) are associated
with the CTSQ domain that is most often significantly related
with (HR)QoL.
Methods
Study population
PERSONAL is a prospective observational multi-center co-
hort study of patients with locally advanced or metastatic (i.e.,
stage IIIB or IV) non-squamous non-small cell lung carcino-
ma (NSCLC) and unresectable mesothelioma treated with
pemetrexed. Patients were recruited from October 2012 to
November 2014 from three teaching hospitals (i.e., Erasmus
University Medical Center, Amphia Hospital, and Sint
Franciscus Gasthuis Hospital) and a regional hospital (i.e.,
Bravis Hospital). Patients were enrolled if they met the
following criteria: they were aged 18 years or older, had a
cytological or histological confirmed diagnosis of advanced
or metastatic (i.e., stage IIIB and IV) NSCLC or unresectable
malignant pleural mesothelioma, and were treated with at least
4 cycles of pemetrexed in combination with a platinum com-
pound as first-line therapy or with at least 4 cycles of
pemetrexed monotherapy as second line. Patients were ex-
cluded if they were not able to read Dutch or could not com-
plete the questionnaires due to a physical or mental condition.
Informed consent was obtained from all individual partici-
pants included in the study. All procedures were in accordance
with the ethical standards of the institutional review board of
the Erasmus University Medical Center in Rotterdam,
The Netherlands (approval number MEC-2012-232), and
with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards.
Procedures
The WHOQOL-BREF and EORTC QLQ-C30 were complet-
ed by patients before the first cycle of chemotherapy, after the
second (days 7 to 14), and after the fourth cycle (days 14 to
21). The CTSQ was completed by patients after the fourth
cycle of chemotherapy simultaneously with the (HR)QoL
questionnaires. In addition, we collected sociodemographic
information (i.e., age, sex, educational level, ethnicity, em-
ployment, partner status (i.e., living or not living together with
a partner)) and clinical information (i.e., Eastern Cooperative
Oncology Group (ECOG) performance status and cancer
stage, type of tumor, line of therapy, and tumor response). In
the four weeks before completion of the CTSQ, the severity
and number of different chemotherapy-related clinical adverse
events that patients experienced were assessed at a weekly
basis according to Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. The information re-
garding these adverse events was collected directly from pa-
tients during patient interviews and from medical records in
the hospital information system.
Study measures
The CTSQ contains three domains covering 16 items: expec-
tations of therapy (five items), feelings about side effects (four
items), and satisfaction with therapy (seven items) [8, 15].
Each item is scored on a Likert scale from 1 (worst response)
to 5 (best response). Four items are reverse coded. Domain
scores range from 0 to 100, with a higher score representing a
better outcome. All patients completed the Dutch translation
of the original English CTSQ [16]. Previous studies have
assessed the psychometric properties in patients with different
forms of cancer, including advanced-stage lung cancer, and
demonstrated good results [15, 16].
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The WHOQOL-BREF [17, 18] is a short version of the
original WHOQOL-100 [19, 20]. It consists of a general facet
(two items) and four domains that represent physical health
(seven items), psychological health (six items), social relation-
ships (three items), and environment (eight items). Each item
is scored on a Likert scale from 1 (worst response) to 5 (best
response). Domains of the WHOQOL-BREF are scored on a
4–20 scale and the general facet on a 2–10 scale with higher
scores indicating a better quality of life [17]. Previous studies
have demonstrated satisfactory psychometric properties of the
WHOQOL-BREF in patients with lung cancer [21] and in
patients with chronic diseases or different forms of cancer
[18] except for the social relationships domain [18, 21].
The EORTC QLQ-C30 is a cancer-specific HRQoL instru-
ment with demonstrated psychometric properties [22] and was
originally developed with lung cancer patients [23]. It consists
of 30 items and incorporates a global health status/QoL scale,
five functional scales, and a number of items assessing addi-
tional symptoms or problems. The functional scales represent
physical functioning (five items), cognitive functioning (two
items), emotional functioning (four items), role functioning
(two items), and social functioning (two items). Each of the
EORTC QLQ-C30 domains is scored on a 0–100 scale, with
higher scores on the functional scales being indicative of bet-
ter HRQoL, whereas higher scores on the symptom scales are
reflective of worse symptoms [23].
Statistics
Patient characteristics were analyzed with descriptive statistics.
Fisher’s exact test was used to compare patients that completed
the CTSQ and (HR)QoL questionnaires with those that did not
on a selection of categorical clinical and sociodemographic var-
iables. For the variables Bage^ and Bgrade 1 or 2 chemotherapy-
related clinical adverse events,^ the independent t test was used.
The Mann-Whitney U test was used for the variable Bgrade 3 or
4 chemotherapy-related clinical adverse events^.
Multiple linear regression analyses were performed to iden-
tify the relationship between expectations of therapy, feelings
about side effects, and satisfaction with therapy with (HR)QoL
without prior simple linear regression analyses given the low
number of independent variables. As no specific data has been
reported in lung cancer, we expected each potential factor to
show a medium effect size. According to Cohen, a correlation
of 0.3 (or R2 = 0.09) constitutes a medium effect [24]. Thus,
given an effect size of R2 = 0.09, a power of 0.80, and an alpha
of 0.05, 69 patients were needed for our main analyses.
Subsequently, simple linear regression analyses were per-
formed to assess the relationship between sociodemographic
(i.e., age, sex, ethnicity, education, employment, partner sta-
tus) and clinical variables (i.e., type of tumor, ECOG perfor-
mance status, cancer stage, and treatment response) and ex-
pectations of therapy, feelings about side effects, or
satisfaction with therapy. Regression analyses were performed
only on the independent variable (i.e., expectations of therapy,
feelings about side effects, or satisfaction with therapy) that
was most often significantly associated with (HR)QoL in the
previous multiple regression analyses.
AP value of 0.05 or lower was considered to be statistically
significant. All analyses were performed with IBM SPSS
Statistics for Windows version 21.0.
Results
Patient selection and characteristics
Of the 177 patients eligible for inclusion, 95 patients (54%)
with stage IIIB or IV NSCLC or mesothelioma completed all
4 cycles of chemotherapy (Fig. 1). Twenty-six of these patients
(26%) did not complete the (HR)QoL questionnaires and/or the
CTSQ. These patients did not differ with the 69 patients (73%)
according to age, sex, ethnicity, education, employment, partner
status, cancer stage, type of tumor, line of therapy, ECOG per-
formance status, and number of different grade 1 or 2 or grade 3
or 4 adverse events. Table 1 summarizes the characteristics of
all 177 patients and the 69 patients used for the analyses.
CTSQ domain scores
The median score of the expectations of therapy domain was
55.0 (interquartile range (IQR) 38.8) and that of the feelings
about side effects domain was 56.3 (IQR 42.2). Satisfaction
with therapy had a median score of 82.1 (IQR 17.9).
(HR)QoL scale and domain scores
Table 2 demonstrates the scores of the different scales and
domains of the EORTC QLQ-C30 and WHOQOL-BREF.
For theWHOQOL-BREF, mean domain scores of the normal-
ly distributed domains were 13.6 (SD 3.1) for physical health
and 16.1 (SD 2.1) for environment. Median scores of the non-
normally distributed domains were 13.7 (IQR 4.0) and 15.3
(IQR 2.7) for, respectively, psychological health and social
relationships. The median score of the general facet was 6.0
(IQR 3.0). Median scores for the different scales of the
EORTC QLQ-C30, including the global health status/QoL
scale, ranged from 50.0 (IQR 50.0) to 83.3 (IQR 33.3).
Adverse events
Table 3 describes the occurrence of different chemotherapy-
related clinical adverse events according to their grade.
Fatigue was the most frequently experienced adverse event
with 87.0% of patients reporting fatigue followed by nausea
(71.0%) and anorexia (63.8%).
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The association of the CTSQ with (HR)QoL
For all domains and scales of the (HR)QoL questionnaires,
except for the WHOQOL-BREF domain social relationships,
the feelings about side effects domain was significantly asso-
ciated with (HR)QoL (Table 4). Positive feelings about side
effects were associated with higher (HR)QoL scores, whereas
negative feelings about side effects related with lower
(HR)QoL. In contrast, high expectations of therapy were only
significantly associated with increased psychological health
and high satisfaction with therapy with solely increased global
health status/quality of life. No other associations between the
(HR)QoL questionnaires and the expectations of therapy and
satisfaction with therapy domain were found.
Eligible patients for inclusion
N=177
Day 1 cycle 1 (baseline)
Patients available to complete 
questionnaires
N=177
Day 14-21 cycle 4
Patients available to complete 
questionnaires 
N=95
Patients excluded
N=0
Cycle 1 to 4
Patients lost due to progression, 
side effects or death 
N=82
Day 14-21 cycle 4
Patients that completed both 
the CTSQ and (HR)QoL 
questionnaires
N=69
Day 14-21 cycle 4
Patients that did not complete 
any of the three questionnaires.
N=25
Patients that did not complete 
the CTSQ
N=1
Enrolled patients
N=199 
Patients staged with IIA, IIB, or 
IIIA and/or who received third 
line, adjuvant or neoadjuvant 
chemotherapy 
N=18
Day 1 cycle 1 (baseline)
Patients that completed the 
(HR)QoL questionnaires 
N=151
Patients not treated with 
chemotherapy
N=4
Analysis
Follow-Up
Patient inclusion
Enrollment
Fig. 1 Selection of patients. N
number of patients, CTSQ Cancer
Therapy Satisfaction
Questionnaire, (HR)QoL (health-
related) quality of life
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Table 1 Patient characteristics
Characteristic All patients (n = 177) Patients that completed
all questionnaires (n = 69)
Patients that did not
complete (all)
questionnaires (n = 26)
P value*
Age, years
Mean (SD) 63.5 (9.0) 62.7 (8.0) 64.4 (9.8) 0.38
Min, max 37, 83 45, 79 37, 78
Sex
Male
Female
94 (53.1)
83 (46.9)
38 (55.1)
31 (44.9)
13 (50.0)
13 (50.0)
0.82
Ethnicity
Caucasian 167 (94.4) 64 (92.8) 24 (92.3) 1.00
Other 10 (5.6) 5 (7.2) 2 (7.7)
Educationa
Low 113 (63.8) 51 (73.9) 18 (69.2) 0.75
High 32 (18.1) 13 (18.8) 3 (11.5)
Unknown 32 (18.1) 5 (7.2) 5 (19.2)
Employment
Yes 39 (22.0) 20 (29.0) 4 (15.4) 0.41
No 112 (63.3) 48 (69.6) 17 (65.4)
Unknown 26 (14.7) 1 (1.4) 5 (19.2)
Partner statusb
Yes 123 (69.5) 59 (85.5) 15 (57.7) 0.18
No 28 (15.8) 9 (13.0) 6 (23.1)
Unknown 26 (14.7) 1 (1.4) 5 (19.2)
Cancer stagec
Locally advanced (IIIB) 21 (11.9) 5 (7.2) 2 (7.7) 0.89
Metastatic (IV) 147 (83.1) 60 (87.0) 22 (84.6)
Other 9 (5.1) 4 (5.8) 2 (7.7)
Type of tumorc
Adenocarcinoma 160 (90.4) 63 (91.3) 21 (80.8) 0.17
Large cell carcinoma, mesothelioma, other 17 (9.6) 6 (8.7) 5 (19.2)
Line of therapy
First line 161 (91.0) 64 (92.8) 24 (92.3) 1.00
Second line 16 (9.0) 5 (7.2) 2 (7.7)
ECOG performance status
Grade 0 or 1 155 (87.6) 66 (95.7) 26 (100.0) 0.20
Grade 2 or higher 21 (11.9) 1 (1.4)
Unknown 1 (0.6) 2 (2.9)
Grade 1 or 2 chemotherapy-related clinical adverse events
Mean 9.2 (3.2) 8.5 (4.0) 0.33
Min, max 3, 19 1, 18
Unknown 1 (1.4)
Grade 3 or 4 chemotherapy-related clinical adverse events
Median 0.0 0.0 0.93
Min, max 0, 4 0, 5
Unknown 1 (1.4)
Values are given in numbers (percentages) unless stated otherwise
n number of patients, SD standard deviation, ECOG Eastern Cooperative Oncology Group
a Low education: persons whose highest level of education is primary education, lower general education, or lower vocational education. High education:
persons whose highest level of education is higher general education, higher vocational education, or university
b Partner status: living or not living together with a partner
cMeasured at baseline
*P values describe differences observed with Fisher’s exact test for all categorical variables and with the independent t test andMann-WhitneyU test for
the variables Bage^ and Bgrade 1 or 2 chemotherapy-related clinical adverse events^ and the variable Bgrade 3 or 4 chemotherapy-related clinical adverse
events^, respectively
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Factors associated with feelings about side effects
In the simple regression analyses, only low-grade chemotherapy-
related clinical adverse events (i.e., grade 1 or 2 adverse events)
were significantly associated with feelings about side effects
(P < 0.01) (Table 5). No other relationship was observed.
Discussion
Preservation of (HR)QoL is an important goal during chemo-
therapy considering that patients with advanced-stage lung
cancer have a limited prognosis [1, 2]. Therefore, identifica-
tion of patients at risk for decreases in (HR)QoL due to treat-
ment may offer opportunities for improvement. We observed,
using a validated scoring system to determine patients’ judge-
ment about therapy in different domains, that negative feelings
about side effects were associated with decreased (HR)QoL.
Especially for patients experiencing low-grade adverse events
at a regularly basis, this seems important.
Of the three CTSQ domains, expectations of therapy, sat-
isfaction with therapy, and feelings about side effects, the last
one was associated with (HR)QoL. In contrast, satisfaction
with therapy was only related with the global health state/
QoL scale of the EORTC QLQ-C30. A reason for this may
be that none of the seven items of the satisfaction with therapy
domain except one (i.e., chemotherapy was worth taking even
with side effects), refer to adverse events or (HR)QoL.
Moreover, patients may associate satisfaction with therapy
with treatment response and survival and not with particular
aspects of (HR)QoL. Since the feelings about side effects do-
main was most often related to (HR)QoL, we studied the un-
derlying factors of this domain. It appeared that the number of
different grade 1 or 2 chemotherapy-related clinical adverse
events was significantly associated. As these were often expe-
rienced on a regularly basis over longer periods of time, vig-
orous management of them is warranted. Therefore, it is rec-
ommended that health care providers have high awareness and
consequently check the occurrence and impact of low-grade
Table 2 Results of the
WHOQOL-BREF and EORTC
QLQ-C30
Questionnaires Number Min, max Mean SD Median IQR
WHOQOL-BREF
Overall QoL/general health 69 3.0, 10.0 6.2 1.7 6.0 3.0
Physical health 67 6.9, 20.0 13.6 3.1 13.7 4.1
Psychological health 68 10.0, 18.7 14.1 2.2 13.7 4.0
Social relationships 68 6.7, 20.0 15.5 2.4 15.3 2.7
Environment 67 11.0, 20.0 16.1 2.1 16.3 3.5
EORTC QLQ-C30
Global health status/QoL 67 8.3, 100.0 57.3 24.6 66.7 41.7
Physical functioning 69 13.3, 100.0 65.1 22.4 66.7 33.3
Role functioning 69 0.0, 100.0 53.1 33.9 50.0 50.0
Emotional functioning 68 16.7, 100.0 75.1 21.5 75.0 25.0
Cognitive functioning 68 0.0, 100.0 77.0 24.4 83.3 33.3
Social functioning 67 0.0, 100.0 74.6 26.8 83.3 33.3
CTSQ
Expectations of therapy 68 15.0, 100,0 58.1 23.8 55.0 38.8
Feelings about side effects 69 12.5, 100 53.7 25.3 56.3 42.2
Satisfaction with therapy 69 42.9, 100 79.6 13.1 82.1 17.9
WHOQOL-BREFWorld Health Organization Quality of Life-BREF Questionnaire, EORTC QLQ-C30 European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, CTSQ Cancer
Therapy Satisfaction Questionnaire, SD standard deviation, IQR interquartile range
Table 3 Ten most frequently reported adverse events according to
CTCAE 3.0
Adverse events Number Grade 1 or 2 Grade 3 or 4
Total 69
Fatigue 60 53 (76.8) 7 (10.1)
Nausea 49 46 (66,7) 3 (4.3)
Anorexia 44 42 (60.9) 2 (2.9)
Altered taste 38 38 (55.1) 0 (0.0)
Mucositis 34 33 (47.8) 1 (1.4)
Dry skin 30 30 (43.5) 0 (0.0)
Constipation 30 29 (42.0) 1 (1.4)
Neuropathy sensory 25 25 (36.2) 0 (0.0)
Dizziness 24 24 (34.8) 0 (0.0)
Rash 21 21 (30.4) 0 (0.0)
Values are given in numbers (percentages)
CTCAE Common Terminology Criteria for Adverse Events
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Table 4 Results of the multiple regression analyses for the WHOQOL-BREF and EORTC QLQ-C30 domains/scales with the CTSQ domains as
variables
Variables Number B SE β P value 95% CI for B R2
WHOQOL-BREF
Overall QoL/general health
ET 68 0.010 0.008 0.143 0.199 − 0.005, 0.026 0.258
FSE 0.031 0.008 0.472 < 0.001* 0.016, 0.046
SWT 0.003 0.015 0.026 0.824 − 0.027, 0.033
Physical health
ET 66 0.017 0.014 0.135 0.217 − 0.010, 0.045 0.309
FSE 0.063 0.014 0.527 < 0.001* 0.036, 0.090
SWT 0.005 0.027 0.022 0.851 − 0.048, 0.059
Psychological health
ET 67 0.020 0.009 0.212 0.032* 0.002, 0.038 0.439
FSE 0.050 0.009 0.578 < 0.001* 0.033, 0.068
SWT 0.015 0.017 0.091 0.377 − 0.019, 0.050
Social relationships
ET 67 0.015 0.013 0.144 0.256 − 0.011, 0.041 0.044
FSE 0.014 0.013 0.141 0.286 − 0.012, 0.039
SWT 0.002 0.025 0.013 0.925 − 0.048, 0.052
Environment
ET 66 0.011 0.011 0.121 0.310 − 0.010, 0.032 0.166
FSE 0.031 0.010 0.364 0.004* 0.010, 0.052
SWT 0.008 0.021 0.052 0.682 − 0.033, 0.050
EORTC QLQ-C30
Global health status/quality of life
ET 66 − 0.018 0.109 − 0.017 0.869 − 0.237, 0.200 0.339
FSE 0.425 0.106 0.442 < 0.001* 0.212, 0.637
SWT 0.478 0.210 0.257 0.026* 0.059, 0.898
Physical functioning
ET 68 0.154 0.103 0.162 0.142 − 0.053, 0.360 0.275
FSE 0.376 0.101 0.421 < 0.001* 0.174, 0.577
SWT 0.237 0.200 0.137 0.240 − 0.162, 0.635
Role functioning
ET 68 0.179 0.147 0.125 0.227 − 0.114, 0.472 0.360
FSE 0.817 0.143 0.607 < 0.001* 0.531, 1.102
SWT − 0.192 0.283 − 0.074 0.499 − 0.758, 0.373
Emotional functioning
ET 67 0.027 0.105 0.030 0.795 − 0.182, 0.237 0.190
FSE 0.347 0.102 0.412 < 0.001* 0.144, 0.550
SWT 0.085 0.201 0.052 0.672 − 0.316, 0.487
Cognitive functioning
ET 67 − 0.043 0.126 − 0.041 0.737 − 0.295, 0.209 0.099
FSE 0.315 0.122 0.329 0.012* 0.071, 0.559
SWT − 0.222 0.242 − 0.120 0.361 − 0.705, 0.260
Social functioning
ET 66 0.019 0.135 0.017 0.887 − 0.251, 0.290 0.149
FSE 0.414 0.131 0.395 0.003* 0.151, 0.677
SWT − 0.061 0.260 − 0.030 0.815 − 0.581, 0.459
CTSQ Cancer Therapy Satisfaction Questionnaire, WHOQOL-BREFWorld Health Organization Quality of Life-BREF Questionnaire, EORTC QLQ-
C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, ET expectations of therapy, FSE feelings
about side effects, SWT satisfaction with therapy
*P values of ≤ 0.05
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adverse events as our results clearly demonstrate that patients
are bothered by them. In contrast, no relation with
chemotherapy-related clinical grade 3 or 4 adverse events
was found. This may be because high-grade toxicities were
much less experienced in this patient cohort and that the study
lacked power. In addition, patients completed the CTSQ after
four cycles of chemotherapy. Patients that experienced severe
complications may have interrupted chemotherapy and were
therefore not included.
Earlier, it was found that HRQoL issues were more often
discussed between doctors and patients when the EORTC
QLQ-C30 was completed by patients than when this was not
the case [13]. All participating physicians and 87% of patients
were interested in the persistent use of the questionnaire.
These results demonstrated the value of questionnaires in on-
cological practice. However, application of such an instrument
does not provide information about what people think and feel
about their treatment. Moreover, (HR)QoL instruments are
often more extended than the 16 items of the CTSQ and re-
quire more time to be completed which hampers their appli-
cation during clinical practice. Also, simply the registration of
adverse events does not provide information about the extent
to which patients are bothered by them. Therefore, consider-
ing the results of this study, we advocate the use of the four
items of the feelings about side effects domain of the CTSQ as
this seems more time efficient and patient friendly.
In the present study, feelings about side effects were more
often significantly associated with (HR)QoL than satisfaction
with therapy. This is an important observation that may be
used by physicians and patients when making treatment deci-
sions. Although several reports reported that patients may ac-
cept a decrease in QoL or treatment-related toxicity given a
possible survival benefit [11, 12], a systematic review demon-
strated that most cancer patients (> 50%) in the included stud-
ies required moderate survival benefits to make chemotherapy
and its risk for toxicity acceptable [25]. Given that, according
to our results, patients with negative feelings about side effects
could have low (HR)QoL and that prognosis is limited in
advanced-stage lung cancer, we propose that the CTSQ results
of previously treated patients may be used to help newly di-
agnosed patients at risk for adverse events (i.e., decreased
performance score, significant comorbidity) in making treat-
ment decisions. For instance, if a considerable proportion of
patients who received chemotherapy were often hampered by
adverse events according to their CTSQ results, newly diag-
nosed patients with a limited prognosis could take knowledge
of these results and make a more considered treatment deci-
sion. In such a way, CTSQ results are handled in a similar
manor during decision making as response and survival rates.
Satisfaction with therapy was significantly associated with
the global health status/QoL scale of the EORTC QLQ-C30
whereas this was not observed for the general facet of the
WHOQOL-BREF. It is possible that this observation ismerely
due to the idiosyncrasies of the data at hand or simply chance.
Also, the relatively small number of patients or selection bias
may be responsible for this. In addition, patients may consider
occurrence and management of adverse events when they
evaluate satisfaction (although this is not directly described
by the items that form the satisfaction with therapy domain).
Given that adverse events can directly affect a patient’s
HRQoL, the interest of health care professionals for adverse
events could influence the relation of satisfaction with therapy
score with the global health status/QoL scale. For instance,
adequate management of adverse events may lead to high
Table 5 Results of the simple regression analyses for the CTSQ FSE domain score
FSE
n B SE β P value 95% CI for B R2
Age 69 − 0.134 0.383 − 0.043 0.728 − 0.899, 0.631 0.002
Sex 69 − 4.968 6.132 − 0.099 0.421 − 17.206, 7.271 0.010
Ethnicity: Caucasian/other 69 − 8.092 11.780 − 0.084 0.494 − 31.606, 15.421 0.007
Type of tumor: adenocarcinoma/other 69 14.368 10.734 0.161 0.185 − 7.058, 35.795 0.026
ECOG performance score: 0 or 1/higher 69 − 23.878 12.787 − 0.222 0.066 − 49.400, 1.644 0.049
Cancer stage: IIIB/IV 69 9.896 9.020 0.133 0.277 − 8.108, 27.899 0.018
Education: low/high 64 0.129 7.730 0.002 0.987 − 15.323, 15.581 0.000
Employment: yes/no 68 8.238 6.659 0.151 0.220 − 5.056, 21.532 0.023
Partner status: yes/no 68 − 6.128 9.025 − 0.083 0.499 − 24.147, 11.890 0.007
Tumor response: complete and partial
response/stable or progressive disease
69 5.525 6.466 0.104 0.396 − 7.382, 18.432 0.011
Grade 1 or 2 chemotherapy clinical AEs 68 − 2.543 0.907 − 0.326 0.007* − 4.354, − 0.733 0.107
Grade 3 or 4 chemotherapy clinical AEs 68 1.527 2.984 0.063 0.610 − 4.430, 7.484 0.004
CTSQ Cancer Therapy Satisfaction Questionnaire, FSE feelings about side effects, ECOG Eastern Cooperative Oncology Group, AE adverse event
*P values ≤ 0.05
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patient satisfaction with their care. This may result in in-
creased satisfaction with therapy scores. Given that treatment
of adverse events could also enhance HRQoL, increased pa-
tient satisfaction with care may result in the observation of an
association between satisfaction with therapy and global
health status/QoL. Expectations of therapy were significantly
associated with psychological health. Besides the possibility
of related constructs, reasons for this may be related to coping.
For instance, in patients with advanced-stage lung cancer,
coping capacity three months after baseline was a predictor
for HRQoL [26]. Patients with good coping capacity may
have high expectations and may value (HR)QoL more posi-
tively than those with few coping capabilities. In addition,
coping style may also be of influence as patients that demon-
strate Ba fighting spirit^ may report higher expectations than
those that have no hope of a good outcome. Moreover, non-
acceptance of the diagnosis and/or prognosis could result in a
paradoxical expression of high expectations.
Some limitations of this study have to be addressed. First,
the included patients were not asked for their motivation to
receive chemotherapy, nor was determined which factors
could influence patients’ treatment preferences and opinions.
This limited us, together with the observational design of this
study and the calculation of associations, to investigate causal
relationships between the CTSQ and the (HR)QoL question-
naires. As the present study is part of a larger project in which
patients’ motivations were not routinely assessed, we could
not provide this information. However, a review that evaluat-
ed cancer patients’ preferences for adjuvant therapy reported
that in addition to treatment benefit and toxicity, personal ex-
perience of the treatment and having dependents (e.g., chil-
dren) were important determinants of patients’ preferences
[27]. Acquiring such information is of importance as it may
help physicians to plan their communication strategy towards
patients and provides opportunities for personalized treatment.
Second, patients treated with less than four cycles of che-
motherapy were not included in this study. These patients
dropped out due to progression or adverse events. Given that
they had to discontinue treatment with chemotherapy earlier
than expected, it is possible that they could have valued satis-
faction with therapy more often as important. This could have
confounded our results and may explain why satisfaction with
therapy in our study was not associated with (HR)QoL.
However, other observational studies in patients with
advanced-stage lung cancer have experienced similar difficul-
ties with patients dropping out during treatment. In addition,
we observed consistent findings regarding the associations of
the CTSQ domains with (HR)QoL. Therefore, the findings of
the present study contribute to the results of the limited num-
ber of reports that discussed the relation of patients’ disease
and treatment-related opinions with (HR)QoL.
Third, the observed R squares of the simple regression
analyses for the feelings about side effects domain in
Table 5 were relatively small. To demonstrate with reasonable
power that the other predictors were truly not a determinant of
feelings about side effects domain score would require the
inclusion of many more patients. Given that the R square of
the analysis in which low-grade adverse events were associ-
ated with feelings about side effects score was relatively high,
suggesting an acceptable power, the result of this analysis
remains of importance.
In conclusion, we demonstrated that patients with
advanced-stage lung cancer who experience strong negative
feelings about side effects have a decreased (HR)QoL. Our
findings demonstrate that low-grade adverse events are of im-
portance for patients’ feelings about side effects. Therefore, it
is recommended that in clinical practice, physicians facilitate
vigorous management of low-grade adverse events to enhance
the (HR)QoL of patients. In addition, the observed results may
aid physicians and patients in making treatment decisions.
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